Biomet Inc.(NASDAQ:BMET) Thursday confirmed Morgan Stanley & Co.Inc.is assisting it in exploring strategic alternatives focused on enhancing shareholder value.The company stated no decisions have been made, and there is no assurance this exploration will result in any specific action. Daniel P.Hann, interim president and chief executive officer, said, "We believe that this review is a prudent exercise and is consistent with management's commitment to our shareholders and team members." The company also stated it does not expect to disclose developments with respect to its exploration of alternatives unless required. Biomet Inc.and its subsidiaries design, manufacture and market products primarily used by musculoskeletal medical specialists in surgical and non-surgical therapy, which are distributed in more than 100 countries.
M.J. RHODES, Times-Union Lifestyles Editor- | July 28, 2016